Views 1,011
Citations 0
Comment & Response
March 10, 2015

Left Atrial Appendage Closure for Atrial Fibrillation

Author Affiliations
  • 1Krankenanstalt Rudolfstiftung, Wien, Austria
  • 2Sana Kliniken, Lübeck, Germany

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;313(10):1057. doi:10.1001/jama.2015.0682

To the Editor The study by Dr Reddy and colleagues1 reported the 3.8-year follow-up of the PROTECT AF trial that randomized patients with atrial fibrillation (AF) to receive percutaneous left atrial appendage (LAA) closure with the WATCHMAN device or warfarin. We had a number of questions and concerns about the study.

First, patients randomized to receive warfarin were older and more often had cardiovascular comorbidities and permanent AF than the patients randomized to receive the LAA closure. In Table 1 in the article, P values were missing, so it is unclear if these differences were statistically significant and may in part explain the higher mortality in the warfarin group.

First Page Preview View Large
First page PDF preview
First page PDF preview